A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.
Also called NCT06897202
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 133 participants
- Sponsor
- Registry
-
NCT06897202
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06897202. Randomized; double masking; primary purpose treatment. Start 2025-03-14 (actual); primary completion 2025-12-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
- Acronym
- VESPER-2
- Condition
- Obesity in Diabetes
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- MET097 Injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct06897202- Content hash
b4b82d27f2c92dc8e612998a17a45e93afd63bc338187d2575c3f0ed3622e1d9